Cargando…

Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience

Background and objectives: Information on the performance of ixekizumab (IXE) in patients with psoriatic arthritis (PsA) in clinical practice is scarce. We aimed to analyze the retention rate and safety of IXE in patients with PsA in routine clinical practice. Methods: A retrospective longitudinal o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braña, Ignacio, Pardo, Estefanía, Burger, Stefanie, González del Pozo, Pablo, Alperi, Mercedes, Queiro, Rubén
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861177/ https://www.ncbi.nlm.nih.gov/pubmed/36675395 http://dx.doi.org/10.3390/jcm12020467

Ejemplares similares

Are Patients with Axial Spondyloarthritis Who Were Breastfed Protected against the Development of Severe Disease?
por: Alonso, Sara, et al.
Publicado: (2023)

Potential Differences in the Cardiometabolic Risk Profile of Patients with Psoriatic Disease according to Their HLA-C∗06 Status
por: Queiro, Rubén, et al.
Publicado: (2022)

Obesity in psoriatic arthritis: Comparative prevalence and associated factors
por: Queiro, Rubén, et al.
Publicado: (2019)

Non-Physical Disease Facets in Spondyloarthritis: An ASAS Health Index-Based Analysis between Psoriatic Arthritis and Axial Spondyloarthritis
por: Queiro, Rubén, et al.
Publicado: (2022)

HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis
por: Queiro, Ruben, et al.
Publicado: (2006)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
por: Miller, John, et al.
Publicado: (2021)

Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study
por: Joven, Beatriz, et al.
Publicado: (2023)

Osteomalacia in Adults: A Practical Insight for Clinicians
por: Arboleya, Luis, et al.
Publicado: (2023)

Clinical Differences between Men and Women with Psoriatic Arthritis: Relevance of the Analysis of Genes and Polymorphisms in the Major Histocompatibility Complex Region and of the Age at Onset of Psoriasis
por: Queiro, Rubén, et al.
Publicado: (2013)

Evaluating standards of care in psoriatic arthritis of the QUANTUM project (qualitative initiative to improve outcomes): results of an accreditation project in Spain
por: García, Emilio Ignacio, et al.
Publicado: (2020)

Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study
por: Murage, Mwangi J., et al.
Publicado: (2021)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
por: Schweikert, Bernd, et al.
Publicado: (2020)

Commentary: Sex-based medicine in psoriatic arthritis: Lessons learned from machine learning-based prediction models
por: Queiro, Rubén
Publicado: (2022)

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population
por: Berman, Julia, et al.
Publicado: (2021)

A comparison of disease impact according to the cardiometabolic risk profile in psoriatic arthritis
por: Queiro, Rubén, et al.
Publicado: (2021)

Differentiated Effect of Smoking on Disease Activity and Quality of Life among Different Spondyloarthritis Phenotypes
por: Alonso-Castro, Sara, et al.
Publicado: (2023)

Gene Variant in the NF-κB Pathway Inhibitor NFKBIA Distinguishes Patients with Psoriatic Arthritis within the Spectrum of Psoriatic Disease
por: Coto-Segura, Pablo, et al.
Publicado: (2019)

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials
por: Mease, Philip, et al.
Publicado: (2019)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

The Region Centromeric to HLA-C Is a Key Region for Understanding the Phenotypic Variability of Psoriatic Arthritis
por: Queiro, Rubén, et al.
Publicado: (2014)

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
por: Gladman, Dafna D., et al.
Publicado: (2019)

Changes in musculoskeletal disease activity and patient-reported outcomes in patients with psoriatic arthritis treated with ixekizumab: results from a real-world US cohort
por: Tillett, William, et al.
Publicado: (2023)

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2020)

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2022)

Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
por: Eder, Lihi, et al.
Publicado: (2022)

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
por: Deodhar, Atul A, et al.
Publicado: (2022)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

Do NSAIDs Take Us Away From Treatment Goals in Axial Spondyloarthritis: A Story About Dysbiosis or Just a Matter of Bias?
por: Queiro-Silva, Rubén, et al.
Publicado: (2021)

The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review
por: Cañete, Juan D., et al.
Publicado: (2020)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021)

Genetic Variants of the NF-κB Pathway: Unraveling the Genetic Architecture of Psoriatic Disease
por: Queiro, Rubén, et al.
Publicado: (2021)

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2021)

Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors
por: Kirkham, Bruce, et al.
Publicado: (2021)

Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study
por: Queiro, Ruben, et al.
Publicado: (2020)

Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study
por: Queiro, Rubén, et al.
Publicado: (2017)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients
por: Moskal, Mateusz, et al.
Publicado: (2022)

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis
por: Combe, Bernard, et al.
Publicado: (2020)

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f0vm3964f33gstag34fre5ra5u